Events Details
Innovent Biologics and Daiichi Sankyo Sign Exclusive China Commercialisation Agreement for VANFLYTA®
Monday, August 10, 2026
Innovent Biologics and Daiichi Sankyo have entered into an exclusive agreement for the commercialisation of VANFLYTA® (quizartinib) in China.
Under the agreement, Daiichi Sankyo will remain responsible for the development, manufacturing and supply of VANFLYTA®, while Innovent Biologics will hold exclusive commercialisation rights in China and lead local market promotion.
VANFLYTA® was approved in China in June 2026 for adults with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD positive, as confirmed by an appropriate validated diagnostic test. The treatment is used in combination with standard cytarabine and anthracycline induction therapy, followed by cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy. The approval was supported by results from the Phase 3 QuANTUM-First trial.
The addition of VANFLYTA® will expand Innovent's haematology portfolio, which already includes TYVYT® (sintilimab injection), HALPRYZA® (rituximab injection), olverembatinib, FUCASO® (equecabtagene autoleucel injection) and Jaypirca® (pirtobrutinib). VANFLYTA® will become the company's 20th commercialised product.
The collaboration combines Daiichi Sankyo's capabilities in drug development and manufacturing with Innovent's commercial infrastructure in China. The companies aim to improve access to VANFLYTA® for patients with newly diagnosed FLT3-ITD-positive AML.
Leukaemia is a major global health concern, with more than 487,000 new cases and over 305,000 deaths reported worldwide in 2022. AML accounts for around 23% of all leukaemia cases globally and is more common in adults.
In China, nearly 82,000 people were diagnosed with leukaemia in 2022, while more than 50,000 deaths were reported. AML is an aggressive form of leukaemia and accounts for approximately half of all leukaemia cases in the country.
FLT3 mutations are among the most common genetic mutations found in AML. Around 80% of FLT3 mutations are FLT3-ITD mutations, which can promote cancer growth and are associated with a higher risk of relapse and shorter overall survival. FLT3-ITD mutations are found in approximately 25% of all AML cases.
Source: innoventbio.com
